Rosetta Genomics Receives Final New York State Approval for Rosetta Kidney Cancer Test

Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of
microRNA-based molecular diagnostics and therapeutics, announced that the New
York State Department of Health ("NYSDOH") has given the Company final approval
for its Rosetta Kidney Cancer Test™ for testing on patient samples from the
State. New York is the only U.S. state that requires an independent regulatory
review process for laboratory-developed tests. Rosetta Genomics has been
offering its Kidney Cancer Test in New York under conditional approval since
December 9, 2013 and now has full approval in all 50 U.S. states. The Kidney
Cancer Test is the Company's proprietary microRNA-based assay that can classify
the four most common kidney tumors: Clear Cell Renal Cell Carcinoma (RCC),
Papillary RCC, Chromophobe RCC and Oncocytoma. With this final approval, each of
Rosetta's cancer testing services now has full New York State approval. 


A blinded independent validation set of 200 samples was studied to measure the
performance of the Rosetta Kidney Cancer Test. Of the 184 samples that produced
a result, 174 were classified correctly demonstrating 95% accuracy or
sensitivity, with 98% specificity. 


"There are approximately 65,000 new cases of primary kidney tumors and 13,000
deaths per year in the United States, and the incidence is rising.
Unfortunately, nearly 25% of patients who have a kidney removed for presumptive
RCC, turn out to have benign oncocytomas, which are safely monitored without
nephrectomy. This failure of pre-operative diagnosis is in part the result of
the small number of pre-operative biopsies, as only about 9-10% of patients have
a pre-operative biopsy. We believe there is an opportunity to improve the
standard-of-care in this setting through the use of our assay," said Kenneth A.
Berlin, President and Chief Executive Officer of Rosetta Genomics. 


"Differential diagnosis between various types of kidney tumors remains
challenging and can lead not only to unnecessary surgeries, but also the
introduction of new, molecularly-targeted therapeutics makes the correct
identification of these subtypes critically important for treatment choice and
for patient selection for clinical trials of new therapeutics in development.
With a sensitivity of 95% and a specificity of 98%, we are confident this assay
can be a useful tool for pathologists and oncologists and we are very pleased to
have final approval to market this important cancer diagnostic for the benefit
of physicians and patients in New York," concluded Mr. Berlin.


About Rosetta Genomics
Founded in 2000, Rosetta's integrative research platform combining
bioinformatics and state-of- the-art laboratory processes has led to the
discovery of hundreds of biologically validated novel human microRNAs. Building
on its strong patent position and proprietary platform technologies, Rosetta is
working on the application of these technologies in the development and
commercialization of a full range of microRNA-based diagnostic tools and
therapeutics. Rosetta currently commercializes a full range of microRNA-based
molecular diagnostics. Rosetta's cancer testing services are commercially
available through its Philadelphia-based CAP-accredited, CLIA-certified lab. For
more information please visit www.rosettagenomics.com.


Forward-Looking Statement Disclaimer
Various statements in this release concerning Rosetta's future expectations,
plans and prospects, including without limitation, Rosetta's Kidney Cancer Test
™, Rosetta's development or commercialization of molecular diagnostics,
prognostic or therapeutic services or tool, the market acceptance of Rosetta's
cancer testing services, particularly the Rosetta Kidney Cancer Test ™, as
well as the utilization of the Rosetta Kidney Cancer Test™ by pathologists or
oncologists, constitute forward-looking statements for the purposes of the safe
harbor provisions under The Private Securities Litigation Reform Act of 1995.
Actual results may differ materially from those indicated by these
forward-looking statements as a result of various important factors, including
those risks more fully discussed in the "Risk Factors" section of Rosetta's
Annual Report on Form 20-F for the year ended December 31, 2013 as filed with
the SEC. In addition, any forward-looking statements represent Rosetta's views
only as of the date of this release and should not be relied upon as
representing its views as of any subsequent date. Rosetta does not assume any
obligation to update any forward-looking statements unless required by law.



FOR FURTHER INFORMATION PLEASE CONTACT: 

Rosetta Genomics Contact: 
Rosetta Genomics 
Ken Berlin
President & CEO 
609-419-9003 
investors@rosettagenomics.com

Investor Contacts: 
LHA 
Anne Marie Fields
212-838-3777
afields@lhai.com

Bruce Voss
310-691-7100
bvoss@lhai.com
Rosetta Genomics (CE) (USOTC:ROSGQ)
Historical Stock Chart
From Mar 2024 to Apr 2024